The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for review to treat adults with virologically suppressed human immunodeficiency ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback